血清诱骗受体 3 γ-干扰素和抗环瓜氨酸肽抗体在风湿性 关节炎患者中的表达及意义

doi:10.3969/j.issn.1006-6233.2019.04.045

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (1607 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the expression and significance of serum decoy receptor 3, interferon-gamma and anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis. Methods: Seventy patients with rheumatoid arthritis admitted to our hospital from February 2017 to December 2017 were selected as observation group, and 65 healthy subjects who received health examination in our hospital during the same period were selected as control group. Fasting venous blood was collected from all subjects on the morning of the 2nd day after admission. The expression of serum decoy receptor 3, interferon-gamma and anti-cyclic citrullinated peptide antibody was detected. The changes and significance of serum decoy receptor 3, interferon-gamma and anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis were analyzed. Results: The serum levels of decoy receptor 3, interferon-gamma and anti-cyclic citrullinated peptide antibodies in the observation group were (4631.05 (+3180.24) pg/mL, (1341.23 (+482.94) pg/mL and (86.51 (+6.38) U/mL, respectively, while those in the control group were (481.53 (+150.07) pg/mL, (248.79 (+62.63) pg/mL and (45.41 (+8.35) U/mL, respectively, with statistical differences (P<0.05); Pearson correlation analysis showed that the serum levels of decoy receptor 3, interferon and anti-cyclic Cit Deception receptor 3, interferon-gamma and anti-cyclic citrullinated peptide antibody levels were positively correlated (r = 0.658, 0.744, P<0.05). Conclusion: The serum levels of decoy receptor 3, interferon-gamma and anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis were significantly increased, and the serum levels of decoy receptor 3, interferon-gamma and anti-cyclic citrullinated peptide antibodies were positively correlated, which could assist in the diagnosis of rheumatoid arthritis.

Key words： Serum decoys receptor 3 Gamma interferon Anti-cyclic citrullinated peptide antibody Rheumatoid arthritis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DENG Qiuping
	MO Qiaoxuan
	JIAN Shaozhen
	et al

Cite this article:

DENG Qiuping,MO Qiaoxuan,JIAN Shaozhen, et al. Expression and Significance of Serum Decoy Receptor 3, Interferon-gamma and Anti-cyclic Citrullinated Peptide Antibodies in Patients with Rheumatic Arthritis[J]. HeBei Med, 2019, 25(4): 699-701.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2019.04.045 OR http://www.hbyxzzs.cn/EN/Y2019/V25/I4/699

[1] Taal E, Rasker J J, Wiegman O. Group education for rheumatoid arthritis patients.[J]. Seminars in Arthritis & Rheumatism, 2017, 26(6):805~816.
[2] Shahrara S, Pickens S R, Dorfleutner A, et al. IL-17 induces monocyte migration in rheumatoid arthritis[J]. Journal of Immunology, 2016, 182(6):3884~3891.
[3] Singh J A, Saag K G, Jr B S, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis.[J]. Arthritis Care Res, 2016, 68(1):1~25.
[4] Burmester G R, Rigby W F, Vollenhoven R F V, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial[J]. Annals of the Rheumatic Diseases, 2016, 75(6):1081~1091.
[5] Ferro F, Elefante E, Luciano N, et al. One year in review 2017: novelties in the treatment of rheumatoid arthritis.[J]. Clinical & Experimental Rheumatology, 2017, 35(5):721~734.
[6] Kobayashi T, Ito S, Kuroda T, et al. The interleukin‐1 and fcγ receptor gene polymorphisms in japanese patients with rheumatoid arthritis and periodontitis[J]. Journal of Periodontology, 2017, 78(12):2311~2318.
[7] Catrina A I, Joshua V, Klareskog L, et al. Mechanisms involved in triggering rheumatoid arthritis[J]. Immunological Reviews, 2016, 269(1):162~174.
[8] Barile A, Arrigoni F, Bruno F, et al. Computed tomography and MR imaging in rheumatoid arthritis.[J]. Radiol Clin North Am, 2017, 55(5):997~1007.
[9] Taylor P C, Keystone E C, Van d H D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis.[J]. N Engl Med, 2017, 376(7):652~662.
[10] Cramp F, Hewlett S, Almeida C, et al. Non-pharmacological interventions for fatigue in rheumatoid arthritis.[J]. Cochrane Database Syst Rev, 2016, 8(8):997~1005.
[11] Solomon J J, Chung J H, Cosgrove G P, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease[J]. European Respiratory Journal, 2016, 47(2):588~596.
[12] Mercan R, Bitik B, Tufan A, et al. The association between neutrophil/Lymphocyte ratio and disease activity in rheumatoid arthritis and ankylosing spondylitis.[J]. Journal of Clinical Laboratory Analysis, 2016, 30(5):597~601.